25-09-2024 | Neuroendocrine Tumor | ASO Research Letter
A Catalog Technique for Hepatic Cytoreductive Interventions in Patients With NETs: Aid for the Future Multidisciplinary Team
Authors:
Alyssa V. Eade, MD, Cathleen E. Hannah, MSN, Lindsay R. Friedman, MD, Tracey Pu, MD, Audra Satterwhite, BSN, Jaydira del Rivero, MD, Jonathan M. Hernandez, MD
Published in:
Annals of Surgical Oncology
Login to get access
Excerpt
Patients with metastatic neuroendocrine tumors (NETs) to the liver are likely to be offered and undergo multiple regional therapeutic interventions due to prolonged survival times and high rates of disease recurrence.
1,2 Regional therapy options include resection, ablation, transarterial bland embolization (TAE), transarterial chemoembolization (TACE), and radioembolization.
3 These treatments can be performed simultaneously (e.g., resection and ablation) or in tandem (e.g., embolization and ablation) to achieve maximal cytoreduction.
4 Complicating the management of these patients is that specialized care often is performed at certain centers (e.g., surgery, histotripsy), whereas patients may be followed at other centers or often at multiple centers throughout the course of their disease. Piecing together interventions, or a combination thereof, that have been implemented for various lesions from procedural reports alone can be challenging. …
